Current thinking on the management of tuberculosis

被引:14
作者
Bastian, I
Stapledon, R
Colebunders, R
机构
[1] Royal Adelaide Hosp, Inst Med & Vet Sci, Adelaide, SA 5000, Australia
[2] Royal Adelaide Hosp, Chest Clin, Adelaide, SA 5000, Australia
[3] Univ Antwerp Hosp, Antwerp, Belgium
关键词
MULTIDRUG-RESISTANT TUBERCULOSIS; ACTIVE ANTIRETROVIRAL THERAPY; FIXED-DOSE COMBINATION; MYCOBACTERIUM-TUBERCULOSIS; COST-EFFECTIVENESS; PULMONARY TUBERCULOSIS; CONTINUATION PHASE; DRUG-TREATMENT; HIV; AFRICA;
D O I
10.1097/00063198-200305000-00006
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
High-income countries are moving toward tuberculosis (TB) elimination. Sophisticated diagnostic tests and effective treatment regimens are readily available. The range of available resources even makes effective treatment of multidrug-resistant tuberculosis (MDRTB) possible. The introduction of highly active antiretroviral therapy and specific TB control measures has reduced the incidence of HIV-associated TB disease. Unfortunately, the situation in low-income countries that carry 95% of the global TB burden is less positive. TB diagnosis still relies upon sputum smear microscopy. The management of MDRTB remains problematic though guidelines for DOTS-plus programs have been developed, and cheaper second-line drugs are becoming available. The HIV epidemic continues to confound TB control efforts, particularly in sub-Saharan Africa. The appropriate package of interventions for controlling HIV/TB disease remains undefined and unimplemented. The international community must provide the funding and technical support to address the alarming dichotomy in TB control that exists between rich and poor countries. (C) 2003 Lippincott Williams Wilkins.
引用
收藏
页码:186 / 192
页数:7
相关论文
共 55 条
[1]   Assessment of bioequivalence of rifampicin, isoniazid and pyrazinamide in a four drug fixed dose combination with separate formulations at the same dose levels [J].
Agrawal, S ;
Kaur, KJ ;
Singh, I ;
Bhade, SR ;
Kaul, CL ;
Panchagnula, R .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2002, 233 (1-2) :169-177
[2]  
Albert H, 2002, INT J TUBERC LUNG D, V6, P529
[3]   In vitro and in vivo activities of gatifloxacin against Mycobacterium tuberculosis [J].
Alvirez-Freites, EJ ;
Carter, JL ;
Cynamon, MH .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (04) :1022-1025
[4]  
[Anonymous], 2000, AM J RESP CRIT CARE, V161, pS221, DOI DOI 10.1080/13506285.2021.1925798
[5]   Evaluation of BACTEC mycobacteria growth indicator tube (MGIT 960) automated system for drug susceptibility testing of Mycobacterium tuberculosis [J].
Ardito, F ;
Posteraro, B ;
Sanguinetti, M ;
Zanetti, S ;
Fadda, G .
JOURNAL OF CLINICAL MICROBIOLOGY, 2001, 39 (12) :4440-4444
[6]   Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study [J].
Badri, M ;
Wilson, D ;
Wood, R .
LANCET, 2002, 359 (9323) :2059-2064
[7]   Predictive model to identify positive tuberculosis skin test results during contact investigations [J].
Bailey, WC ;
Gerald, LB ;
Kimerling, ME ;
Redden, D ;
Brook, N ;
Bruce, F ;
Tang, SH ;
Duncan, S ;
Brooks, CM ;
Dunlap, NE .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 287 (08) :996-1002
[8]   Tuberculosis in patients with HIV infection [J].
Barnes, PF ;
Lakey, DL ;
Burman, WJ .
INFECTIOUS DISEASE CLINICS OF NORTH AMERICA, 2002, 16 (01) :107-+
[9]  
Benator D, 2002, LANCET, V360, P528, DOI 10.1016/S0140-6736(02)09742-8
[10]  
Blomberg B, 2001, B WORLD HEALTH ORGAN, V79, P61